An open-label, randomized, 48-week study to assess the safety, tolerability and activity of raltegravir when replacing the ritonavir-boosted PI [protease-inhibitor] component of HAART [highly active antiretroviral therapy] in HIV-infected individuals with viral load suppression on a ritonavir-boosted PI containing regimen
Latest Information Update: 06 Nov 2015
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals; Atazanavir; Darunavir; Fosamprenavir; HIV protease inhibitors; Indinavir; Lopinavir; Ritonavir; Saquinavir; Tipranavir
- Indications HIV-1 infections
- Focus Biomarker; Therapeutic Use
- Acronyms SPIRAL
- 08 Mar 2012 Biomarker and lipid profile results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
- 22 Nov 2011 Results of the 86 patients included in the SPIRAL-LIP substudy have been reported in AIDS.
- 18 Jul 2010 Results were presented at the 18th International AIDS Conference